Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus local chemotherapy and drug-eluting bead bronchial artery chemoembolization for unresectable locally advanced NSCLC
ChiCTR2600135133Phase 4Not yet recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iparomlimab and tuvonralimab in non-small cell lung cancer (NSCLC), sponsored by Hunan Cancer Hospital. Primary endpoint: Objective response rate. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600135133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135133.